Integrating the Patient Perspective Into Value Frameworks
|
|
- Shana Fowler
- 5 years ago
- Views:
Transcription
1 Integrating the Patient Perspective Into Value Frameworks Avalere Health An Inovalon Company August, 2017
2 Speakers and Agenda Josh Seidman, PhD Senior Vice 1. The Need for the Patient Perspective in Existing Value Frameworks 2. A Multi-Faceted Approach to Developing the PPVF 3. The Current State and Evolution of PPVF Pilots and Use Cases 4. Questions? 2
3 The Need for the Patient Perspective in Existing Value Frameworks
4 The Current Value Framework Landscape Value assessment critical as US healthcare transitions from volume to value Proliferation of value frameworks in 2015 Today s value frameworks range from focusing on oncology (e.g., ASCO, MSK, NCCN) to specialty drugs and devices more broadly (e.g., ICER) Developers refining frameworks in response to patients, payers, providers, and manufacturers o Industry (as represented by AdvaMed, BIO, NPC, and PhRMA) published guiding principles in Spring 2016 o Patient groups have also joined the conversation (e.g., NHC s Value Rubric and Avalere/FasterCures Patient-Perspective Value Framework, PPVF) ASCO: American Society of Clinical Oncology MSK: Memorial Sloan Kettering NCCN: National Comprehensive Cancer Network ICER: Institute for Clinical and Economic Review BIO: Biotechnology Innovation Organization NPC: National Pharmaceutical Council NHC: National Health Council 4
5 Frameworks Differ in Aim, Conditions, and Audience Intended Users Therapeutic Focus Stated Aim ASCO Providers Patients Oncology Develop physician-guided tool to assess benefits and toxicities of drugs in relation to their costs to assist in shared decision-making with patients ICER Payers Policymakers Multiple Provide a framework to guide payers in assessment of the value of drugs, medical devices, and procedures MSK Providers Patients Oncology Determine appropriate prices for cancer drugs based on multiple value components NCCN Providers Patients Oncology Provide visual representation of 5 key aspects of evidence 5
6 Under ASCO s Framework, Value Assessment Is Based on a Drug s Net Health Benefit Score Users are encouraged to evaluate the score and direct drug cost side by side Hazard ratio (HR) for death is the preferred statistic used to assess the efficacy of a treatment. All adverse events - scored by frequency and grade - are considered to assess toxicity. Clinical benefit score Net health benefit score Toxicity score Input from Healthcare Industries Bonus points* Provided for: Improvements in palliation of symptoms Treatment free intervals Improvements in QoL QoL: Quality of Life Schnipper L. E., et al Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology. Link. 6
7 Drug Abacus Price Reflects Eight Domains, Modifiable within a Given Range Efficacy Toxicity Novelty R&D Improvement in overall OS or surrogate Frequency/ severity of side effects Mechanism of action / delivery / next-in-class Cost of development Rarity Pop Health Burden Unmet Need Prognosis Incidence of disease Years of life lost in US pop Social need for a drug Severity of the disease OS: Overall Survival DrugPricing Lab, Memorial Sloan Kettering. Methodology. Link. 7
8 NCCN s Value Framework Evaluates New Cancer Drugs Based on Five Categories of Evidence NCCN Evidence Blocks Categories and Definitions* 5 E Efficacy of Regimen/Agent E S Q C A S Q C A Safety of Regimen/Agent Quality of Evidence Consistency of Evidence Affordability of Regimen/Agent *For example purposes only National Comprehensive Cancer Network To date, NCCN has published Evidence Blocks for 42 of their 47 clinical guidelines, which are a key resource that providers use when making treatment decisions. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks. Link. 8
9 ICER s Value Assessment Framework Considers Both Long-Term Value and Short-Term Affordability Goal: Sustainable Access to High-Value Care for All Patients Long-Term Value for Money Short-Term Affordability Comparative Clinical Effectiveness Estimated Incremental Cost- Effectiveness Potential Budget Impact Other Benefits or Disadvantages Contextual Considerations ICER. Value Assessment Framework for Link. 9
10 Payer Familiarity with ICER is High, but is Not the Driving Factor in Coverage Determinations ICER Familiarity Shown: All Payers 100% % Degree to which ICER factored into coverage plans Shown: Payers familiar, somewhat familiar, or not that familiar with ICER framework 9% 2% 0% 1% 60% 29% 40% 61 19% 20% 18 0% 40% Very Familiar Not That Familiar Never Heard of It Somewhat Familiar Not Familiar at All The The Single Biggest Determining Factor, 0% 0% A Significant Factor, But Not the Biggest Barely a Factor Among the Biggest Factors A Minor Determining Factor Not a Factor at All Do Not Know Totals do not add to 100% due to rounding Q: How familiar would you say you are with The Institute for Clinical and Economic Review s Value Assessment Framework, also referred to as ICER s Value Assessment Framework? Q: Overall considering all of the decisions surrounding therapies that your organization has made in the past year, how much have ICER s value frameworks factored in to your plans decision to cover a therapy? See Appendix for full survey methodology. 10
11 Looking Forward, Payers Generally Anticipate Using the ICER Framework in Some Capacity Health plans can leverage value assessments at many points during the decision-making process, from supplementing P&T committee evaluations to strengthening price negotiations Likelihood of Using ICER Framework in the Next Year Shown: All Payers 15% 50% 33% 2% Very Likely Somewhat Likely Not Very Likely Not Likely At All Q: Separate from how you described the plan s decisions in the past year, were there any instances where an ICER value framework was especially relevant to deciding on a therapy? Q: How likely are you to use ICER s value frameworks in a year from now See Appendix for full survey methodology. 11
12 How Frameworks Could Be More Appealing to Payers Frameworks for the payer audience will need to have methodological transparency, consider total treatment cost, integrate real-world data, and facilitate physician-patient dialogue Considerations that would make payers more likely to use an external value framework Shown: All Payers Having a better understanding of the value framework s methodology 68% If the value framework considered total treatment cost If the value framework considers real world data as well as randomized controlled trial data 57% 56% If the value framework can be used at the point of care between physician and patient 40% If the value framework considers the patient perspective 31% Frameworks that extend across many therapeutic areas 19% None of the above 4% Q: Which of the following would make you more likely to use a value framework in the future? (Select all that apply.) See Appendix for full survey methodology. 12
13 A Multifaceted Approach to Developing the Patient-Perspective Value Framework
14 The Patient-Perspective Value Framework Initiative WHERE WE VE BEEN AND WHERE WE RE GOING In Phase I, the PPVF Steering Committee built PPVF to fill a gap in the value framework space PPVF to be implemented and used by various decisionmakers seeking to define and measure value from the patient s perspective Avalere analysis determined that existing value frameworks do not adequately incorporate and measure the patient s perspective on value In Phase II, Avalere and FasterCures aim to refine, test and validate the PPVF and apply it to real-world settings 2015 Phase I Phase II Phase III Forward Identify Gap in Existing Frameworks Build PPVF Version 1.0 Refine, Test, & Validate Implement PPVF: Patient-Perspective Value Framework Additional information available here: 14
15 Phase I Approach: An Iterative, Collaborative Process PHASE I FOCUSED ON BUILDING THE FRAMEWORK P4C Conference Steering Committee formed Draft PPVF Released 100 public comments received Patient outreach Collaboration with other framework developers PPVF Version 1.0 release Nov 2015 June 2016 Nov 2016 Dec 2016 Jan 2017 Feb 2017 May 2017 Value frameworks emerged as a pressing topic to various stakeholders Coalesced around a common goal: defining value from the patient s perspective Received over 60% of comments from patients and patient advocates Conducted conditionspecific focus groups and surveys Interactive meeting with framework developers including ASCO and NCCN P4C: Partnering for Cures 15
16 Multi-Stakeholder Steering Committee Guides PPVF Initiative The steering committee convenes regularly to provide feedback on the PPVF and guide next steps * * * In addition to the above organizations, leadership and staff from across the Centers for Medicare and Medicaid Services (CMS) will participate in meetings and provide input to the framework. * denotes a verbal commitment formal membership is being finalized 16
17 Overview / The Patient-Perspective Value Framework The PPVF has five broad domains, which contribute different types of information to the framework Patient Preferences Quality & Applicability of Evidence Patient-Centered Outcomes Patient & Family Financial Considerations Usability & Transparency 17
18 Multifaceted Approach to Gathering Input on the PPVF We conducted the below activities to pressure test the PPVF beyond our steering committee: Feedback Mechanism Participants % Patients/ Caregivers Public Call for Feedback 96 63% Roundtable with Patient Advocates % American Heart Association/American Stroke Association (AHA) Citizen Scientist Think Tank 4 100% Michael J. Fox Foundation Survey 31 97% Cancer Support Community Focus Group 8 100% American Heart Association/American Stroke Association (AHA) Survey % TOTAL % Moving forward, we will heavily rely on human-centered design to implement and test the PPVF in real-world settings 18
19 The Current State and Evolution of PPVF Pilots and Use Cases
20 Phase II and Beyond: Future Applications of the PPVF Shared Decision Making Shared decision-making tool to support conversations between patients and clinicians Apply to Existing Frameworks Apply to existing value frameworks to better incorporate the patient perspective into value assessment Support Public Healthcare Programs Support public healthcare programs through shared decision making applications and others Strategic Internal Analyses Guide internal strategic analyses and potential future conditionspecific analyses Other Applications Each PPVF application will be used to inform other applications and future versions of the PPVF 20
21 Shared Decision Making Pilot / Developing a Shared Decision-Making Tool Aim: Develop/test decision-support tool that addresses the full spectrum of patientoriented value and fully integrates into the clinician s workflow and patient s life flow Phase 1 Phase 2 Phase 3 Phase 4 Identifying Partners, Pilot Sites and Conditions Developing the Shared Decision Making Tool Piloting the PPVF Decision Aid Evaluating the Intervention Partners Needed Content & Technology Clinical Payer (data) As we develop specific shared decision-making applications, we will pay special attention to overcoming the limitations associated with patient and clinician burden 21
22 Apply to Existing Frameworks Use Case / Collaborating with Other Framework Developers Aim: Integrate PPVF into other value frameworks to address gaps in patient-centered value considerations Map PPVF to Value Equation of Other Frameworks in collaboration with framework developers Evaluate methodologies of other frameworks Identify specific gaps in patientcentered value considerations Recommend Adjustments in collaboration with PPVF Steering Committee Develop targeted methodological recommendations to address gaps Partner to Implement Adjustments Provide support to implement and publish PPVF-based adjustments to other frameworks The PPVF Steering Committee has actively engaged with existing framework developers throughout the process 22
23 Support Public Healthcare Programs Pilot / Developing & Implementing a PPVF Checklist Aim: Develop/test a paper-based checklist that can be deployed as a patientfacing educational and engagement resource Develop & Test the PPVF checklist with patients & families using humancentered design Implement the PPVF checklist in real-world settings e.g., engage hospitals/ practices across HIINs and TCPI Evaluate the implementation and publish results Scale e.g., submit as a MIPS improvement activity for inclusion in the Quality Payment Program Focus group results with cancer patients and survivors showed they would benefit from a checklist outlining range of patient-centered aspects of value to be considered when making decisions about treatment options HIIN: Hospital Improvement Innovation Network TCPI: Transforming Clinical Practice Initiative MIPS: Merit-Based Incentive Payment System 23
24 Support Public Healthcare Programs Use Case / Developing Patient-Centered Measures Aim: Identify gaps in measures that are most meaningful to patients/families, among measures currently being used by public payers Map existing PROMs, patient experience measures, and shared decision-making measures against the PPVF Develop a report outlining identified gaps in patient-centered measures and suggestions for how to improve them/develop de novo measures Support public/private payers in guiding their measure identification, selection and development process The PPVF is a valuable tool to guide mapping exercises and gap analyses, given that it was developed in collaboration with and vetted by a multi-stakeholder Steering Committee PROMs: Patient-Reported Outcome Measures 24
25 Strategic Internal Analyses Use Case / Driving Patient-Centered Drug Development Aim: Partner with researchers and life sciences companies to evaluate the patient-centeredness of current and future healthcare products Select Therapeutic Area of Focus Identify areas that will have broad impact, e.g., cross-section of cancers and chronic conditions Conduct Gap Analysis Identify gaps in patientcentered evidence base within the therapeutic areas of focus Outline Recommendations Suggest next steps for improving evidencegeneration strategies for outcomes that matter to patients By collaborating with industry partners, the PPVF could ultimately drive patient-centeredness in the development of new healthcare products 25
26 Questions?
27 We Look Forward to Partnering with You Josh Seidman, PhD Senior Vice
Current Landscape: Value Assessment Frameworks. Kimberly Westrich, MA Vice President, Health Services Research
Current Landscape: Value Assessment Frameworks Kimberly Westrich, MA Vice President, Health Services Research Updated June 2016 Background There are many aspects to the U.S. health care system, as well
More informationPatient-Centered Measurement: Innovation Challenge Series
Patient-Centered Measurement: Innovation Challenge Series Learning Collaborative 2018 Webinar Thursday, March 1, 2018 1 Hala Durrah, MTA Patient Family Engagement Consultant, Speaker & Advocate 3 2017-18
More informationValue-based frameworks in oncology
28 November 2017 Value-based frameworks in oncology Clarity or confusion? Prepared for: European Statistical Meeting on Latest Trends in HTA Prepared by: Jan McKendrick, Senior Director PRMA Consulting
More informationIncreasing Adult Immunization Rates in the US Through Data and Quality: A Roadmap
Increasing Adult Immunization Rates in the US Through Data and Quality: A Roadmap Avalere Health An Inovalon Company November 16, 2017 In Partnership with GSK Agenda 1 2 3 4 5 Welcome & Introductions Overview:
More informationProgress from the Patient-Centered Outcomes Research Institute (PCORI)
Progress from the Patient-Centered Outcomes Research Institute (PCORI) Anne Beal, Chief Operating Officer of the Patient-Centered Outcomes Research Institute Sharon-Lise Normand, Vice Chair, Methodology
More informationEvolution of the Oncology Landscape. Emerging Trends and Focus on Value
Emerging Trends and Focus on Value 2 Introduction Owing to advances in early detection and treatment of cancer, people are living longer after a cancer diagnosis. Consequently, this has led to a growing
More informationThe Academy Capitol Forum: Meet the Experts. Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved
The Academy Capitol Forum: Meet the Experts Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved Presenter: Gregory Martin, Deputy Directory of Stakeholder Engagement
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationConsumer Participation Plan Summary
Consumer Participation Plan Summary 2013-2016 Table of Contents 1. Summary... 1 6. Consumer, Carer and Community Participation Plan... 3 6.1 Aim... 3 6.2 Objectives... 3 6.3 Strategies... 4 7. Strategies
More informationNew Jersey Department of Human Services Quarterly Newsletter Division of Mental Health Services June 2006
Dear Mental Health Community, On February 10, 2006, the Division of Mental Health Services released a Wellness and Recovery Transformation Statement guiding the direction for future activities of New Jersey
More informationRGP Operational Plan Approved by TC LHIN Updated Dec 22, 2017
RGP Operational Plan 2017-2018 Approved by TC LHIN Updated Dec 22, 2017 1 Table of Contents Introduction... 1 Vision for the Future of Services for Frail Older Adults... 1 Transition Activities High Level
More informationMJFF S VISION FOR PARTNERING WITH PATIENTS. Sohini Chowdhury The Michael J. Fox Foundation
MJFF S VISION FOR PARTNERING WITH PATIENTS Sohini Chowdhury The Michael J. Fox Foundation OUR SINGLE, URGENT GOAL: CURE PARKINSON S DISEASE MJFF s Mission The Michael J. Fox Foundation is dedicated to
More informationCommunity Development Division: Funding Process Study Update
Community Development Division: Funding Process Study Update Background and Context Two key research studies the Race to Equity Report and a study of Madison s Social Sector by Joiner Sandbrook LLC--highlighted
More informationBotswana Private Sector Health Assessment Scope of Work
Example of a Scope of Work (Botswana) Botswana Private Sector Health Assessment Scope of Work I. BACKGROUND The Republic of Botswana is a stable, democratic country in Southern Africa with an estimated
More informationUsing Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC
Using Health Economics to Inform the Development of Medical Devices Matthew Allsop MATCH / BITECIC Overview Background to MATCH Overview of health economics in product development Concepts relating to
More informationIntroduction. Legislation & Policy Context
Consumer Participation Plan 2017-2018 1 Introduction Barwon South Western Regional Integrated Cancer Service (BSWRICS) is committed to improving the experiences and outcomes of those affected by cancer
More informationNew England QIN-QIO Patient and Family Advisor Council. 2017: A Year in Review
New England QIN-QIO Patient and Family Advisor Council 2017: A Year in Review The Origins The Center for Medicare & Medicaid Services (CMS) is at the forefront of the nationwide effort to: transform health
More informationOncology Clinical Pathways: Making Treatment Decisions in the Era of Patient-Centered, Personalized Cancer Care June 12, 2017
Oncology Clinical Pathways: Making Treatment Decisions in the Era of Patient-Centered, Personalized Cancer Care June 12, 2017 Moderator: Daryl Pritchard, Ph.D. Vice President, Science Policy Personalized
More informationPursuing Quality Lives
Pursuing Quality Lives Supporting Ohioans with Autism Across Agencies, Across the State, Across the Lifespan May 2018 Interagency Work Pursuing Quality Group Lives on Autism1 Ohio has a rich and long-standing
More informationWhat is a Special Interest Group (SIG)?
PATIENT REPORTED OUTCOMES RESEARCH SPECIAL INTEREST GROUP Open Meeting 20 th Annual European Congress November 6, 2017 Glasgow, Scotland What is a Special Interest Group (SIG)? Member-driven group interested
More informationMinistry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 1 Section 1.08 Ministry of Health and Long-Term Care Palliative Care Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of Actions Recommended Actions
More informationFLORIDA S NO WRONG DOOR (NWD) SYSTEM PLANNING PROJECT
FLORIDA S NO WRONG DOOR (NWD) SYSTEM PLANNING PROJECT Agenda No Wrong Door (NWD) Planning Project Update Agencies Inventory Stakeholder Survey Planning and Service Area (PSA) Visits NWD System State Plan
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationProvincial Cancer Control Advisory Committee
Provincial Cancer Control Advisory Committee Annual Performance Report 2012-2013 Table of Contents 1.0 Overview... 4 2.0 Shared Partnerships... 7 3.0 Highlights and Accomplishments... 7 4.0 Report on
More informationLiving Evidence Network
Living Evidence Network Governance Structure Adopted July 2018 Trusted evidence. Informed decisions. Better health. Living Evidence Network: Governance Structure 2 Contents Background 3 About the Living
More informationDedicated to research, education and service to patients for prevention and effective treatment of kidney disease
STRATEGIC PLAN Our Mission: Dedicated to research, education and service to patients for prevention and effective treatment of kidney disease Introduction Over the last 2 years, the Trustees undertook
More informationApril 1, Dear Members of the Pain Management Best Practices Inter-Agency Task Force,
April 1, 2019 U.S. Department of Health and Human Services Office of the Assistant Secretary for Health 200 Independence Avenue, S.W., Room 736E, Attn: Alicia Richmond Scott, Task Force Designated Federal
More informationIntroduction to the Patient- Centered Outcomes Research Institute
Introduction to the Patient- Centered Outcomes Research Institute Laura Forsythe, PhD, MPH Senior Program Officer, Research Integration and Evaluation 1 About PCORI pcori.org/about About PCORI An independent
More informationViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV
ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status
More informationPatient Involvement in Drug Coverage Review Ontario Public Drug Programs Patient Evidence Submissions
Patient Involvement in Drug Coverage Review Ontario Public Drug Programs Patient Evidence Submissions Sherry O Quinn A/Senior Manager, Drug Benefits Management Ontario Public Drug Programs Ministry of
More informationSection #3: Process of Change
Section #3: Process of Change This module will: Describe a model of change that supported the development and implementation of a palliative care program in long term care. Describe strategies that assisted
More informationCANCER LEADERSHIP COUNCIL
CANCER LEADERSHIP COUNCIL A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS ADDRESSING PUBLIC POLICY ISSUES IN CANCER November 17, 2015 Andy Slavitt Acting Administrator Centers for Medicare
More informationSTRATEGIC PLAN
STRATEGIC PLAN 2016 2020 Promoting and supporting excellence in research www.immunology.org BSI STRATEGY 2016 2020 EXECUTIVE SUMMARY OUR MISSION Our mission is to promote excellence in immunological research,
More informationGlobal Action Against Dementia: Finding a Path Forward and the World Dementia Council
Global Action Against Dementia: Finding a Path Forward and the World Dementia Council Raj Long MBPsS MSc Vice Chair World Dementia Council ASAD Hangzhou October 2016 1 Overview 1. Global State of Dementia
More informationEHR Developer Code of Conduct Frequently Asked Questions
EHR Developer Code of Conduct Frequently Asked Questions General What is the purpose of the EHR Developer Code of Conduct? EHR Association (the Association) members have a long tradition of working with
More informationSITC Accomplishment Report for An Overview of the Society s Strategic Plan Activities and Accomplishments to Date
SITC Accomplishment Report for 2013 An Overview of the Society s 2012-2015 Strategic Plan Activities and Accomplishments to Date SITC 2012 2015 Strategic Plan Overview The Society for Immunotherapy of
More informationOral Health: An Essential Component of Primary Care. Executive Summary
Oral Health: An Essential Component of Primary Care Executive Summary June 2015 Executive Summary The Problem Oral health is essential for healthy development and healthy aging, yet nationwide there is
More informationHow to Integrate Peer Support & Navigation into Care Delivery
How to Integrate Peer Support & Navigation into Care Delivery Andrew Bertagnolli, PhD Care Management Institute Why Integrate Peer Support into the Care Delivery Pathway? Improved health Increased feelings
More informationCOVERAGE WITH EVIDENCE DEVELOPMENT
COVERAGE WITH EVIDENCE DEVELOPMENT OVERVIEW AND USE TO PROMOTE BIOMARKER DEVELOPMENT IOM National Cancer Policy Forum Sean Tunis, MD, MSc November 10, 2014 CED DEFINITION AND PURPOSE Reimbursement that
More informationBusiness Contributions to Setting New Research Agendas: Business Platform for Nutrition Research (BPNR)
Business Contributions to Setting New Research Agendas: Business Platform for Nutrition Research (BPNR) Purpose How can we promote more investment into public research? How can we promote improved uptake
More informationNHC Webinar Series on Clinical Outcome Assessments. Patient-Reported Outcomes and Patient-Centered Outcomes: Is There a Difference?
NHC Webinar Series on Clinical Outcome Assessments Patient-Reported Outcomes and Patient-Centered Outcomes: Is There a Difference? NOVEMBER 7, 2018 Outline Why are we having this webinar? Introduction
More informationBringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA
Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence March 27 2018 IIeX Health, Philadelphia, PA Overview Current Landscape Data Sources to generate Real
More informationAgenda. Illinois Diabetes Action Plan: What s In It for You? 10/27/2017
Illinois Diabetes Action Plan: What s In It for You? AADE IL Coordinating Body 4th Annual Symposium Making Noise About Diabetes Bloomington, IL November 3, 2017 Agenda The Burden of Diabetes IL Diabetes
More informationMember-centered cancer care In Georgia
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Member-centered cancer care In Georgia Ira Klein, MD, MBA, FACP GASCO Annual Meeting September 5, 2015 > One
More informationTransition to Cancer Survivorship
Transition to Cancer Survivorship Zach Moore Dr. Barbara Norton FMSRE 2017- Project #1 Cancer Diagnosis Cancer Treatment Surgery Radiation Chemotherapy Cancer Survivor https://images.google.com/?gws_rd=ssl
More informationStrategic Plan Executive Summary Society for Research on Nicotine and Tobacco
Strategic Plan 2013 2017 Executive Summary Society for Research on Nicotine and Tobacco Prepared By: Corona Insights Corona Insights, 2012 CoronaInsights.com CONTENTS Introduction... 1 Background... 1
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More information7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities
7th Mena Influenza Stakeholders Meeting WHO Influenza Strategy Development and Vaccine-related Research Priorities Wenqing Zhang 9 10 September 2017 Riga, Latvia 1 Seasonal influenza 1 billion cases yearly
More informationRe: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 25, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationIntroduction. Arthritis Foundation Arthritis Advocacy Toolkit
Introduction As a Champion of Yes, you can help knock down barriers to easy and affordable care and use your Yes attitude to make a difference. Amplify your message by adding your voice to ours. The actions
More informationEvaluations. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services. Disclosure Statements.
Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services June 21, 2012 Featured Speaker David Hoffman M.Ed. C.C.E, NYS DOH Office of Health Insurance Programs Clinical Associate
More informationCommunity Benefit Strategic Implementation Plan. Better together.
Community Benefit Strategic Implementation Plan 2016 2019 Better together. Table of Contents Introduction... 4 Priority 1: Community Health Infrastructure... 5 Objective 1.1: Focus resources strategically
More informationGEO Service Provider Advisory Council ( Advisory Council )
GEO Service Provider Advisory Council ( Advisory Council ) Purpose Serve as an advisory body to GEO regarding service provider needs, marketplace developments, etc. Serve as a conduit for fresh ideas and
More informationStudy protocol. Version 1 (06 April 2011) Ethics ref: R&D ref: UK CRC portfolio ID:
Identifying and prioritising important research questions for the treatment of eczema a collaborative partnership between patients, carers, clinicians and researchers Study protocol Version 1 (06 April
More informationPage 1 of 8. CFS:2009/2 Rev.2. CFS 2017/44/12/Rev.1.
Date: 29 March 2018 Time: 09:30-12.30 & 14.00 17.00 Location: Red Room, FAO HQ (Building A, 1st Floor) I. INTRODUCTION 1. The Committee on World Food Security (CFS) carried out the reform in 2009 so that
More informationImplementing Performance Measurement Programs: The Blue Cross Blue Shield of Massachusetts Perspective
Implementing Performance Measurement Programs: The Blue Cross Blue Shield of Massachusetts Perspective Dana Gelb Safran, Sc.D. Senior Vice President Performance Measurement and Improvement Massachusetts
More informationWhat do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden
What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden Sunil Ramkali Account Director, W Communication Agency 11 th November 2014
More informationPARTNERS FOR A HUNGER-FREE OREGON STRATEGIC PLAN Learn. Connect. Advocate. Partners for a Hunger-Free Oregon. Ending hunger before it begins.
Learn. Connect. Advocate. PARTNERS FOR A HUNGER-FREE OREGON STRATEGIC PLAN 2016-18 Partners for a Hunger-Free Oregon Ending hunger before it begins. Dear Partners, This has been a year of celebration,
More informationAlberta Children s Hospital Patient and Family Engagement Model
Alberta Children s Hospital Patient and Family Engagement Model At Alberta Children s Hospital we have many years of experience in engaging patients and families as active partners to create better healthcare
More informationIMPACT APA STRATEGIC PLAN
IMPACT APA STRATEGIC PLAN I am very proud to be a psychologist. Most in psychology chose this field for the pursuit of knowledge and to make an impact, and I ve seen firsthand how psychology affects practically
More informationPatient-Centered Outcomes Research Institute
Patient-Centered Outcomes Research Institute Grayson Norquist, PCORI Board of Governors Sherine Gabriel, PCORI Methodology Committee (chair) Institute of Medicine Clinical Effectiveness Research Innovation
More informationSoftware as a Medical Device (SaMD)
Software as a Medical Device (SaMD) Clinical Evaluation IMDRF/SaMD WG (WD2)/N41R1: 2016 Bakul Patel, USA FDA Chair SaMD Working Group Scope NWIE Proposal - Software as a Medical Device (SaMD): Clinical
More informationPart 1: Introduction & Overview
Part 1: Introduction & Overview We envision a collaborative, participative partnership around IDU that: Provides all relevant and interested stakeholders with a voice and role. Promotes awareness of the
More informationPeople and Communities Board. Six principles for engaging people and communities. Definitions, evaluation and measurement
People and Communities Board Six principles for engaging people and communities Definitions, evaluation and measurement June 2016 Published by the People and Communities Board, with support from National
More informationU.S. Strategic Framework on Multiple Chronic Conditions ANAND PAREKH, M.D., M.P.H.
U.S. Strategic Framework on Multiple Chronic Conditions ANAND PAREKH, M.D., M.P.H. DEPUTY ASSISTANT SECRETARY FOR HEALTH U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES JUNE 22, 2011 U.S. Challenge Prevalence
More informationKNOWLEDGE VALORIZATION
KNOWLEDGE VALORIZATION The goal of this valorisation chapter is to describe how the knowledge resulting from the research in this dissertation can be made valuable for clinical and social use. This dissertation
More informationMRCG Strategic Document
MRCG Strategic Document 2015-2016 The Medical Research Charities Group (MRCG) is an umbrella group of medical research and patient support charities that seeks to generate dynamic medical research in Ireland,
More informationIllinois Diabetes Action Plan: What s In It for You?
Illinois Diabetes Action Plan: What s In It for You? AADE IL Coordinating Body 4th Annual Symposium Making Noise About Diabetes Bloomington, IL November 3, 2017 Agenda The Burden of Diabetes IL Diabetes
More informationClinical Pathways in the Oncology Care Model
Clinical Pathways in the Oncology Care Model Centers for Medicare & Medicaid Services Innovation Center (CMMI) Andrew York, PharmD, JD Faculty Andrew York, PharmD, JD Social Science Research Analyst Patient
More informationDuring the Health Issues Centre conducted a project for the Ministerial Taskforce for Cancer. This project aimed to:
Consumer Participation Plan 2015-2016 Introduction Barwon South Western Regional Integrated Cancer Service (BSWRICS) is committed to improving the experiences and outcomes of those affected by cancer in
More informationConsumer Participation Strategy
Consumer Participation Strategy Plan Implementation Period 2011-2013 Date: 24 December 2010 Developed by: NEMICS Directorate in consultation with Acknowledgements and thank you to: s, Dr Ian Roos (Cancer
More information10 Steps to a Successful Town Hall Meeting
DIABETES LEGISLATIVE TOOLKIT 2 ND EDITION 10 Steps to a Successful Town Hall Meeting How-To Guide to Hosting a diabetes Town Hall When it comes to diabetes, engaging the community is no easy undertaking.
More informationLocal Healthwatch Quality Statements. February 2016
Local Healthwatch Quality Statements February 2016 Local Healthwatch Quality Statements Contents 1 About the Quality Statements... 3 1.1 Strategic context and relationships... 5 1.2 Community voice and
More informationAnalysis of Federal Research Investments in Breast Cancer & the Environment Research
Analysis of Federal Research Investments in Breast Cancer & the Environment Research Purpose To understand investment Goals Gaps Overlaps Methodology Used classification coding systems currently available
More information1201 Maryland Avenue SW Suite 900 Washington, DC
June 14, 2012 Lonnie King, D.V.M. Chair Committee on Identifying and Prioritizing New Preventive Vaccines for Development Institute of Medicine 500 Fifth Street, NW Washington, DC 20001 Re: Ranking Vaccines:
More informationBuilding a Digital Home to Provide Patient Support, Education and Clinical Trial Awareness
Building a Digital Home to Provide Patient Support, Education and Clinical Trial Awareness unlocking the potential of multi-stakeholder communities and the families it serves Rare Drug Development and
More information1. Improve Documentation Now
Joseph C. Nichols, MD, Principal, Health Data Consulting, Seattle, Washington From Medscape Education Family Medicine: Transition to ICD-10: Getting Started. Posted: 06/19/2012 Target Audience: This activity
More informationTrends in Oncology: Preparing for Seismic Change. ASCO s Clinical Affairs Department
Trends in Oncology: Preparing for Seismic Change Association of Northern California Oncologists May 20, 2015 Thomas R. Barr, MBA Director, Business Metrics and Analysis Clinical Affairs Department ASCO
More informationCancer prevention and control in the context of an integrated approach
SEVENTIETH WORLD HEALTH ASSEMBLY A70/A/CONF./9 Agenda item 15.6 25 May 2017 Cancer prevention and control in the context of an integrated approach Draft resolution proposed by Brazil, Canada, Colombia,
More informationAt the Intersection of Public Health and Health Care: CDC s National Asthma Control Program
At the Intersection of Public Health and Health Care: CDC s National Asthma Control Program Shirl Ellis Odem Maureen Wilce Elizabeth Herman Asthma Initiative of Michigan Partnership Forum June 3, 2016
More informationOpportunity and Challenge
Opportunity and Challenge Implementation of Comparative Effectiveness Research: The Patient Protection and Affordable Care Act Dr. Ellen V. Sigal, Chair & Founder, Friends of Cancer Research Comparative
More informationPresenters: Robin Newhouse Steven Goodman David Hickam
Managing the Mass of Measures: Real People s Real Data Made Useful PCORI Methodology Report: Setting the Standard(s) for Rigorous, Patient- Centered Research June 3, 2014 12:00 1:00 pm EDT Presenters:
More informationSummary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well
More informationAccess to Dental Care Summit March 23 25, 2009
March 3, 2008 Access to Dental Care Summit March 23 25, 2009 entered an alternate universe HRSA Regional Dental Consultant Captain, U.S. Public Health Service Senior Manager Access, Community Oral Health
More informationBy 2020, cancer care costs are projected to reach approximately
RESEARCH Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology Bijal Shah-Manek, BPharm, PhD; Joseph
More information2018 Fall NAMD Meeting Washington Hilton 1919 Connecticut Avenue, NW Washington, DC November 12-14, 2018
Preliminary DRAFT AGENDA 2018 Fall NAMD Meeting Washington Hilton 1919 Connecticut Avenue, NW Washington, DC 20009 November 12-14, 2018 Monday, November 12, 2018 State Only Day 8:00 AM - 5:00 PM Registration
More informationNovember 9, 2018 Karen Kmetik, PhD Group Vice President, Improving Health Outcomes
AMA Academic Physicians Section Improving Health Outcomes Update November 9, 2018 Karen Kmetik, PhD Group Vice President, Improving Health Outcomes 1 The urgency: The national numbers are large and growing
More informationALBERTA CLINICAL RESEARCH CONSORTIUM Strategic Plan Phase II STRATEGIC PLAN PHASE II
ALBERTA CLINICAL RESEARCH CONSORTIUM Strategic Plan Phase II 2018-2020 STRATEGIC PLAN PHASE II 1 Our vision is high quality, integrated, and efficient clinical health research in Alberta ALBERTA CLINICAL
More informationMinnesota Cancer Alliance SUMMARY OF MEMBER INTERVIEWS REGARDING EVALUATION
Minnesota Cancer Alliance SUMMARY OF MEMBER INTERVIEWS REGARDING EVALUATION Minnesota Cancer Alliance Comprehensive Cancer Control Program P.O. Box 64882 St. Paul, MN 55164 651-201-3661 lisa.gemlo@state.mn.us
More informationADVOCACY IN ACTION TO ACHIEVE GENDER EQUALITY AND THE SUSTAINABLE DEVELOPMENT GOALS IN KENYA
ADVOCACY IN ACTION TO ACHIEVE GENDER EQUALITY AND THE SUSTAINABLE DEVELOPMENT GOALS IN KENYA Wherever inequality lives, there stands a girl or woman able to turn the tide of adversity into a tidal wave
More informationAccess to cancer drugs: The role for a stakeholder alliance?
Access to cancer drugs: The role for a stakeholder alliance? John Zalcberg Co-Chair, Cancer Drugs Alliance (CDA) Disclosures Research support, travel support and honoraria from a wide variety of pharmaceutical
More informationMinistry of Children and Youth Services. Independent Clinical Review Process for the Ontario Autism Program. Guidelines
Ministry of Children and Youth Services Independent Clinical Review Process for the Ontario Autism Program Guidelines January 2018 Copies of this report can be obtained from: Ontario.ca/autism 2 Table
More informationNATIONAL QUALITY FORUM
National Voluntary Consensus Standards for Patient Outcomes Summary of the Eye Care Technical Advisory Panel Conference Call March 25, 2010: 10:00-11:00PM Eastern Standard Time TAP members participating:
More informationThe Prime Minister s Challenge on Dementia Lorraine Jackson Deputy Director: Dementia Policy Department of Health 12 April 2016
The Prime Minister s Challenge on Dementia 2020 1 Lorraine Jackson Deputy Director: Dementia Policy Department of Health 12 April 2016 Costs and impact of dementia Estimated 676,000 people in England with
More informationComprehensive Cancer Control Technical Assistance Training and Communication Plan. PI: Mandi Pratt-Chapman, MA. Cooperative Agreement #1U38DP
Comprehensive Cancer Control Technical Assistance Training and Communication Plan PI: Mandi Pratt-Chapman, MA Cooperative Agreement #1U38DP004972-01 July 2014 Acknowledgement: This work was supported by
More informationPalliative Care Quality Standard: Guiding Evidence-Based, High-Quality Palliative Care in Ontario Presented by: Lisa Ye, Lead, Quality Standards,
Palliative Care Quality Standard: Guiding Evidence-Based, High-Quality Palliative Care in Ontario Presented by: Lisa Ye, Lead, Quality Standards, Health Quality Ontario Candace Tse, Specialist, Quality
More informationSmart BJA Initiatives and the Role of the Research Partnership
Smart BJA Initiatives and the Role of the Research Partnership Ed McGarrell, Ph.D. Michigan State University Faye S. Taxman, Ph.D. George Mason University Welcome and Introductions Welcome & Overview of
More information10 questions to ask if you re scrutinising......arrangements for effective local Healthwatch
10 questions to ask if you re scrutinising......arrangements for effective local Healthwatch The Centre for Public Scrutiny The Centre for Public Scrutiny is an independent charity that promotes transparent,
More informationPatient and Public Involvement in JPND Research
Patient and Public Involvement in JPND Research A user-friendly guide for applicants to JPND Calls for proposals January 5 2015 Created in conjunction with DenDRoN, United Kingdom Purpose The purpose of
More informationRICHLAND COUNTY MENTAL HEALTH AND RECOVERY SERVICES
RICHLAND COUNTY MENTAL HEALTH AND RECOVERY SERVICES 5-YEAR STRATEGIC PLAN SUMMARY 2017 TO 2022 Mission Statement The mission of the Richland County Mental Health and Recovery Services Board is to facilitate
More information